Kalvenox (Amoxicillin, Clavulanic Acid)

• Kalvenox, a combination beta‑lactam antibiotic, is indicated for infections caused by susceptible bacteria across several organ systems.
• Acute bacterial sinusitis: shortens disease duration and relieves nasal congestion, facial pressure, and purulent discharge.
• Acute otitis media: eradicates middle‑ear pathogens, decreasing pain, fever, and risk of complications.
• Community‑acquired pneumonia: provides bacterial clearance, improving cough, fever, and oxygenation in adult patients.
• Uncomplicated urinary tract infections: eliminates uropathogens, leading to rapid resolution of dysuria, frequency, and urgency.
• Skin and soft tissue infections: treats cellulitis and wound infections, reducing erythema, swelling, and systemic signs.

• Amoxicillin binds to penicillin‑binding proteins on the bacterial cell wall, inhibiting the transpeptidation step of peptidoglycan synthesis, which weakens the wall and leads to cell lysis. Clavulanic acid, a β‑lactamase inhibitor, covalently binds to bacterial β‑lactamase enzymes, preventing them from hydrolyzing amoxicillin and thereby extending its antibacterial spectrum against β‑lactamase‑producing organisms. This synergistic action results in a broader coverage of Gram‑positive and Gram‑negative pathogens, including those that would otherwise inactivate amoxicillin alone.

Kalvenox may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild stomach upset often occurring after the first dose.
• Diarrhea: loose stools that may be self‑limiting.
• Vomiting: occasional emesis, especially if taken on an empty stomach.
• Rash: mild skin erythema or itching.
• Headache: transient headache without neurological signs.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction with airway compromise.
• Clostridioides difficile‑associated diarrhea: potentially life‑threatening colitis.
• Hepatic enzyme elevation: abnormal liver function tests.
• Stevens‑Johnson syndrome: severe mucocutaneous reaction.
• Neutropenia: marked reduction in neutrophil count.
• Serum sickness‑like reaction: fever, arthralgia, and rash after several days of therapy.

• When prescribing Kalvenox, clinicians should consider several precautionary measures to ensure safe use.
• Renal impairment: adjust dose according to renal function and monitor creatinine.
• Hepatic disease: use with caution and monitor liver enzymes.
• History of penicillin allergy: avoid use due to risk of hypersensitivity.
• Concomitant oral contraceptives: efficacy may be reduced; advise additional contraceptive methods.
• Pregnancy and lactation: prescribe only if benefits outweigh potential risks.
• Store at below 25°C: keep in the original container, protect from moisture and light.

Kalvenox can interact with other medicines, altering its efficacy or increasing toxicity.

Major Interactions (Avoid)

• Allopurinol: increased risk of severe skin rash.
• Methotrexate: enhanced toxicity leading to bone marrow suppression.
• Warfarin: potentiation of anticoagulant effect, requiring INR monitoring.

Moderate Interactions (Monitor Closely)

• Oral contraceptives: reduced hormonal effectiveness, risk of unintended pregnancy.
• Probenecid: decreased renal clearance, raising amoxicillin plasma levels.
• Aminoglycosides: additive nephrotoxic potential, monitor renal function.